ABSTRACT
The effect of synthetic inhibitors of matrix metalloproteinases (MMP) has been shown against a variety of tumors in preclinical models. Ro 28-2653, a novel synthetic MMP inhibitor, is able to reduce tumor growth in orthotopic prostatic cancer in rats (R3327 Dunning tumor). However, at present this inhibitory mechanism in tumor inhibition in vivo can only be partly explained by the inhibition of the catalytic activity of MMPs overexpressed in cancereous tissue. Using the flow cytometric method, we have investigated the effect of various concentrations of Ro 28-2653 on the Dunning tumor cells with regard to the staining of F-actin and DNA as markers of apoptosis. In combination with fluorescence microscopy we detected the loss of F-actin and the degradation of internucleosomal DNA. This effect of Ro 28-2653 on apoptosis was dose- and time-dependent increasing with concentration between 10 and 100 microg/ml as well as with time of treatment between 24 and 48 h.
Subject(s)
Apoptosis/drug effects , Matrix Metalloproteinase Inhibitors , Piperazines/pharmacology , Protease Inhibitors/pharmacology , Pyrimidines/pharmacology , Actins/metabolism , Animals , DNA/metabolism , Dose-Response Relationship, Drug , Flow Cytometry , Male , Matrix Metalloproteinases/metabolism , Prostatic Neoplasms/metabolism , Rats , Tumor Cells, CulturedABSTRACT
Description of two techniques for electrofusion of myeloma and spleen cells in order to produce a higher yield of hybridoma in comparison with the classical methods.
